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Background: The impact of Target-specific oral anticoagulants (TSOACs) on mortality outcomes compared to warfarin remains unclear. 
The objective of this study was to estimate the rate of fatal bleeding, case-fatality rate of major bleeding and compare mortality outcomes in 
patients treated with TSOACs versus warfarin.
methods: We searched for phase III, randomized controlled trails (RCTs) comparing TSOACs to warfarin (target international normalized 
ratio [INR], 2.0 to 3.0) in patients with atrial fibrillation or venous thromboembolism.
results: Twelve RCTs involving 102 607 patients were included in the analysis. The case-fatality rate of major bleeding was 7.57% [95% 
CI, 6.53-8.68] in patients taking TSOACs and 11.0% [95% CI, 9.20-13.10] in patients taking warfarin. The rate of fatal bleeding in patients 
receiving TSOACs was 0.1 per 100 patient-years [95% CI, 0.13-0.27]. When compared with warfarin, TSOACs were associated with 
significant reduction in fatal bleeding (RR, 0.53 [95% CI, 0.43-0.64]; P<0.001; I2 = 0%), cardiovascular mortality (RR, 0.88 [95% CI, 0.82-
0.94]; P=0.0002; I2 = 0%) and all-cause mortality,Figure 1 (RR, 0.91 [95% CI, 0.86-0.95]; P<0.001; I2 = 0%).
conclusion:  In a meta-analysis of RCTs, the use of TSOACs was associated with lower risk of case-fatality rate of major bleeding, fatal 
bleeding, cardiovascular mortality and all-cause mortality when compared to therapeutic warfarin (target INR between 2.0 to 3.0).
